How Bio­con Bi­o­log­ics is tak­ing on the US biosim­i­lars mar­ket

Bio­con Bi­o­log­ics is bet­ting big that it can be a top US biosim­i­lars com­pa­ny.

With its $3 bil­lion ac­qui­si­tion of Vi­a­tris’ biosim­i­lar port­fo­lio last No­vem­ber now ful­ly in­te­grat­ed, Bio­con is ready­ing a more con­cert­ed com­mer­cial push.

It’s up against some 800-pound go­ril­las — the es­tab­lished and mar­ket­ing-savvy Big Phar­ma biosim­i­lar com­pa­nies like Am­gen, No­var­tis, Pfiz­er and Bio­gen. But Bio­con isn’t new to mar­ket­ing biosim­i­lars in the US, thanks to its 10-year part­ner­ship with Vi­a­tris. To­geth­er, they launched the first biosim­i­lar to Am­gen’s Neu­las­ta, Ful­phi­la (peg­fil­gras­tim), in 2018, fol­lowed by the first biosim­i­lar ri­val to Genen­tech block­buster Her­ceptin, called Ogivri (trastuzum­ab) in 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER